Intended for healthcare professionals
Search
Toggle navigation
Current issue
Archive
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
Editorial board
For authors
Advertising
Contact us
News
Web Exclusives
Register
FREE
Sign in
×
Remember me
Not registered?
Forgot your password?
Therapeutic options for seborrhoeic dermatitis
Ian H Coulson
A chronic relapsing condition affecting about 3–5% of the adult population, seborrhoeic dermatitis is defined by its appearance. The pink-red patches with an overlying greasy scale in the eyebrows, over the scalp and hairline, around the nasolabial folds spreading onto the cheeks, and the presternal, intrascapular and retroauricular lesions should need no introduction to this readership. Scalp lesions may range in severity from mere dandruff to full-blown pityriasis amiantacea.
Dermatology in practice
2003;
11
(5): 16–18
To continue reading this article, please
sign in
or
register
.
Follow us on
|
|
Latest News
LEO Pharma receives MHRA approval for Anzupgo cream in chronic hand eczema
Galderma shares positive phase 3 data for nemolizumab in prurigo nodularis
J&J/Protagonist’s icotrokinra shows promise in phase 3 plaque psoriasis trial
UCB’s Bimzelx approved by FDA to treat hidradenitis suppurativa
LEO Pharma announces long-term results for Adbry in atopic dermatitis
This site uses cookies in order to function properly and to allow us to improve our service. By using this site you consent to the use of cookies as set out in our
privacy policy